EHA 2022 | The safety and efficacy of AUTO1/22: a novel co-transduced CD19/22 CAR-T therapy for R/R ALL
Sara Ghorashian
• 12 Jun 2022
Sara Ghorashian, PhD, MD, FRCP, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, shares some insights into the efficacy of AUTO1/22, a novel, co-transduced CD19/22 CAR-T cell therapy for the treatment of relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Dr Ghorashian first comments on the role of CD19 negative escape in relapsed disease, and then discusses the efficacy of AUTO1/22 and the promise of dual-targeting treatment approaches. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis, UCLB
